News & Notices
Organizations
& People
Standing Committees
Divisions
Projects
Reports
Publications
Symposia
..Application for Sponsorship
..Visas
AMP
Links
of Interest
Search
the Site
Home
Page |
|
Pure Appl. Chem., Vol. 70, No. 11,
pp. 2120, 1998
Pharmaceutical bioprospecting and its relationship
to the conservation and utilization of bioresources*
Howard G. Wildman
AMRAD Discovery Technologies Pty. Ltd., 576 Swan Street, Richmond,
Victoria, Australia 3121
E-mail: [email protected]
Abstract: There may be a perception amongst conservationists
and the public that large quantities of material are
being collected from the bush or the oceans for screening for novel
natural products. Whilst small amounts of material may be used for
the initial stages of the drug discovery process, there is a clear
desire within the pharmaceutical industry to conserve the worlds
biota so that more species can be examined for novel chemical molecules
and, that compounds of interest are produced via routes that do
not involve the destructive and costly harvesting of samples. This
presentation compares and contrasts biodiversity, conservation and
sampling issues involved in examining different types of biota for
the production of novel natural products of pharmaceutical value.
Examples of some natural products produced by microorganisms, plants
and other macroorganisms are discussed to illustrate the bioresource
conservation and utilization requirements of the pharmaceutical
industry and how these differ for the different types of organisms.
Download full text (9 pages)
- PDF file (40KB)
* Invited lecture presented at the International
Conference on Bioversity and Bioresources: Conservation and
Utilization, 23-37 November 1997, Phuket, Thailand.
Page last modified 15 April 1999.
Copyright ©1997, 98, 99 International Union of Pure and Applied
Chemistry.
Questions or comments about IUPAC, please contact, the Secretariat.
Questions regarding the website, please contact Web Help.
|